CRISPR Medicine News, 23 October 2020 | Your Missing Links - CRISPR Medicine

Your missing links are here

Top Picks


  • Researchers from Germany and the US develop compact Cascade–Cas3 system for targeted genome engineering. The system that can make larger genomic deletions than is possible with CRISPR-Cas9, with applications in research and potential for gene insertion and replacement strategies within agriculture and therapy.
  • US research team use in vivo delivery of an adenine base editor and a single guide RNA targeting a single mutation to restore sight in adult mice with the inherited retinal disease retinitis pigmentosa. Research findings published in Nature Biomedical Engineering.
  • US and Australian researchers use CRISPR to validate genetic targets that may be used in control strategies against Culex moquitoes, a globally widespread vector of human and animal pathogens. Research findings shared on preprint server bioRxiv.
  • Computer scientists at University of Oxford report crisprSQL, a novel database platform for CRISPR/Cas off-target cleavage assays. The free resource, found here, is an interactive and bioinformatically enhanced collection of CRISPR/Cas9 off-target cleavage studies that aims to support the fields of cleavage profiling, gene editing safety analysis and transcriptomics. Read the research article here.




Vision and Opinion


Clinical Trials


Heh, huh wow

CRISPR Medicine Jobs is Here!

We recently launched the first targeted recruitment platform for CRISPR-related jobs. Prospective employers and job seekers from all over the world can use this unique platform to find highly skilled scientists and exciting jobs within the CRISPR Medicine field!

Check out the first external job posting from the Hendel Lab in Israel right here.

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at We love hearing from readers!

Happy Reading!


p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.